Accuray's CyberKnife approved in Japan
This article was originally published in Clinica
Accuray's CyberKnife G4 robotic radiosurgery system has received approval ("shonin") from the Japanese Ministry of Health, Labor and Welfare (MHLW). The system, which will be marketed as the CyberKnife Radiosurgery System, can noninvasively treat tumours anywhere in the body, including the head and neck. It uses image-guidance technology to deliver high-dose radiation to tumours while minimising damage to healthy tissue. The original CyberKnife system was first approved in Japan in1996 for head and neck tumours; this was expanded in 2008 to include all extracranial tumours (www.clinica.co.uk, 24 June 2008). The G4 system is better at coping with target movement than pervious versions, Sunnyvale, California-based Accuray claims, further minimising the radiation dose to healthy tissue. It also allows a 50% reduction in treatment times.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.